<DOC>
	<DOCNO>NCT00112060</DOCNO>
	<brief_summary>This phase I/II , multi-centered , non-randomized trial design determine safe dose PT-523 subject , make preliminary evaluation activity PT-523 therapy subject NSCLC .</brief_summary>
	<brief_title>A Study Assess Safety Preliminary Efficacy PT-523 Patients With Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Age â‰¥ 18 year Histologically cytologically confirm NSCLC stage III stage IV , recurrent disease , fail therapy standard first line ( Phase I/II ) well second line chemotherapy regimen ( Phase I ) , intolerant standard chemotherapy . Receipt one additional prior chemotherapy regimen neoadjuvant , adjuvant , neoadjuvant plus adjuvant allowable . A prior epidermal growth factor receptor tyrosine kinase inhibitor ( EGFRTK ) antagonist allowable ( Phase II ) . Asymptomatic treat brain metastasis ( include steroid ) last therapy receive &gt; 4 week study entry deem investigator low likelihood rapid deterioration . ECOG performance status 0 2 . Adequate organ function bone marrow reserve . Use appropriate contraceptive method . Signed patient inform consent . Investigational agent within 30 day prior Day 1 study . Known symptomatic uncontrolled brain metastasis . Uncontrolled intercurrent illness . Known human immunodeficiency virus ( HIV ) , hepatitis A , B , C , D E. Patient uncontrolled pleural effusion . Patient receive nitrosoureas mitomycinC within 6 week chemotherapy radiation therapy within 3 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Talotrexin</keyword>
	<keyword>PT-523</keyword>
	<keyword>Non-Small Cell Lung Carcinoma ( NSCLC )</keyword>
</DOC>